Physician profile
Mit V Patel
NPI 1740721950
$1,630.38
in general payments reported to CMS, 2019-2025
19 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.94 · 2022: $112 · 2023: $115 · 2024: $741 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,420.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.28 | 2022-2025 | Jardiance |
| Amgen INC. | $252.29 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $174.31 | 2024-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $126.90 | 2021-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $121.71 | 2023-2024 | |
| Philips North America LLC | $119.49 | 2023-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Pfizer INC. | $93.98 | 2024-2025 | |
| Daiichi Sankyo INC. | $86.89 | 2024-2025 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $64.37 | 2025 | Uptravi, Opsynvi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $45.71 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $44.63 | 2024-2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.05 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $24.90 | 2024 | Wainua |
| Abbott Laboratories | $24.15 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $24.13 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $18.09 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $17.82 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2025 | |
| Merck Sharp & Dohme LLC | $15.62 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.